{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_16808", "batch_size": 36, "batch_pos": 33, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 2, "answer": "no", "rationale": "The segment describes deal details, not using high-potency language.", "method": "llm_batch", "batch_id": "batch_2_17024", "batch_size": 198, "batch_pos": 195, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 3, "answer": "no", "rationale": "No moderate verb from the list is present.", "method": "llm_batch", "batch_id": "batch_3_19964", "batch_size": 114, "batch_pos": 111, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 4, "answer": "no", "rationale": "The segment contains no question.", "method": "llm_batch", "batch_id": "batch_4_17348", "batch_size": 105, "batch_pos": 102, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 5, "answer": "no", "rationale": "Lacks explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_19380", "batch_size": 99, "batch_pos": 96, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_19828", "batch_size": 38, "batch_pos": 35, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 7, "answer": "no", "rationale": "The segment describes details of a vaccine deal and does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_8468", "batch_size": 9, "batch_pos": 6, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 8, "answer": "yes", "rationale": "Describes details of securing doses, which is preparedness/resource acquisition.", "method": "llm_batch", "batch_id": "batch_8_17896", "batch_size": 136, "batch_pos": 133, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
